Kawasaki disease
Conditions
Interventions
Intervention group:The combination treatment of low-dose methylprednisolone (2mg/kg/day q12h) and intravenous immunoglobulin (2g/kg)
Control group:The basic treatment of intravenous immunoglobulin (2g/kg)
Sponsors
West China Second University Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
No minimum to 10 Years
Inclusion criteria
Inclusion criteria: (1) The legal guardian shall provide a written informed consent form according to the requirements of the region or the Institutional Review Board (IRB); (2) Patients who meet the diagnostic criteria for Kawasaki disease of the American Heart Association (AHA) in 2017, and are under 10 years of age; (3) Patients did not receive any Kawasaki disease-related treatment within 10 days after the onset of the disease; (4) Patients with Kawasaki disease meet the criteria for high-risk IVIG resistance as follows, NLR>11.7, CRP>170mg/L, Na25µmol/L, ALT>250 U/L, AST >177 U/L.
Exclusion criteria
Exclusion criteria: (1) The disease duration of patients with Kawasaki disease was more than 10 days; (2) Patients received IVIG or steroid treatment at other hospitals; (3) Patients were diagnosed with cardiac shock or macrophage activation syndrome (MAS), which requires the early application of the high-dose steroid treatment, etc; (4) Patients had the contraindications of steroids and/or IVIG, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The fever at 48 hours after IVIG treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| CALs;The changes of inflammatory indexes; | — |
Countries
China
Contacts
Public ContactLiu Xiaoliang
West China Second University Hospital, Sichuan University
Outcome results
None listed